The 10 latest articles on Clinical Trials (Phases I–IV) come from 7 sources, published between Oct 1 and Nov 13. Most come from MarketScreener (3) and markets.businessinsider.com (2).
Organizations: FDA (2)
Places: Chicago (2), Munich (2), Germany (2), MD (2)
TipRanks Nov. 9, 2026, 09:50 AM Zealand Pharma (ZLDPF) announced that Boehringer Ingelheim has reported results from the Phase 3 SYNCHRONIZE-CVOT trial, the first and only global cardiovascular safety trial of a glucagon/GLP-1 dual agonist to date. The trial met its primary endpoint…
Rezolute has completed enrollment in phase 3 clinical trial evaluating its experimental drug ersodetug in tumor hyperinsulinism, with preliminary results expected by mid-December, it said late... Biotechnology & Medical Research Rezolute Says Phase 3 upLIFT Study Fully Enrolled, Topline Data Due Mid-December Published…
This is a paid press release. Contact the press release distributor directly with any inquiries. Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component…
Published on 10/01/2026 at 05:02 pm EDT Nektar Therapeutics announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria in two oral…
FOSTER CITY, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the positive 52-week clinical results from the Phase 3 ASC40-304 open-label extension of denifanstat in…
Published: November 12, 2026By LLLaura LitwiniStock.com/yacobchuk A recent study published in JAMA Dermatology reported findings from an evaluation of a “response-pattern-guided optimization framework” to guide treatment decision-making for patients with hidradenitis suppurativa (HS) who achieved only a partial response to…
News Conference News AHA 2026 SCOUT-HCM: Mavacamten Maintains Benefits Through 56 Weeks The cardiac myosin inhibitor has the potential to transform the lives of children with obstructive HCM, Joseph Rossano says. By Todd Neale November 12, 2026 CHICAGO, IL—Mavacamten (Camzyos; Bristol Myers Squibb)…
marketscreener.com Cullinan Says Partner Submits New Drug Application for Zipalertinib Combination for Certain Form of Lung Cancer Published on 11/12/2026 at 05:37 pm EST
A biochemical response to ursodeoxycholic acid (UDCA) at 12 months was associated with lower 5-year risks of hepatic decompensation and mortality in patients with primary biliary cholangitis (PBC), a propensity-matched landmark cohort study suggested. Among patients considered to be responders -- defined…
By Benjamin Eddie Published: Nov 12 2026, 11:34 AM EST Esma Melike Sezer/Unsplash.com The FDA's deadline to act on ivonescimab — a biologic drug that physically changes shape inside a tumor to become more effective — lands this Saturday, November 14. If approved, it…
Design, endpoints, enrollment, interim reads, and post‑market surveillance.
An article joins this feed when it matches these terms. Each one is also a search of its own.